Angiotensin-converting enzyme inhibitor, beta-blocker,mineralocorticoid receptor antagonist and SGLT2 inhibitors are referred to as the‘four pillars’ of medical management for heart failure with reduced ejectionfraction (ejection fraction ≤40%). This evidence concerns the gene SLC5A2 and heart failure.